Basis: Latest reported fiscal quarter. Source: stored company filings and market data; unavailable inputs remain N/A.
Is the debt to assets ratio high or low?
The debt to assets ratio of 28.79% is 12% below its 5-year average of 32.74%, near the low end of its 5-year range (27.83%–56.77%).
As of the fiscal period ended Tuesday, June 30, 2026. 10.71% below its 12-month average of 32.24%.
Reported quarterly debt to assets ratio; no daily interpolation. Q2 FY2026 (2026-06-30): 28.79%.
DEBT TO ASSETS RATIO
28.79%
DEBT TO ASSETS RATIO AVG TTM
32.24%
DEBT TO ASSETS RATIO AVG 3Y
32.87%
DEBT TO ASSETS RATIO AVG 5Y
32.74%
DEBT TO ASSETS RATIO AVG 10Y
32.89%
DEBT TO ASSETS RATIO AVG 15Y
N/A
DEBT TO ASSETS RATIO AVG 20Y
N/A
CURRENT VS TTM AVG
-10.71%
CURRENT VS 3Y AVG
-12.41%
CURRENT VS 5Y AVG
-12.07%
CURRENT VS 10Y AVG
-12.46%
CURRENT VS 15Y AVG
N/A
CURRENT VS 20Y AVG
N/A
SECTOR MEDIAN · HEALTHCARE
0.11%
median of 526 covered companies
CURRENT VS SECTOR MEDIAN
+27317.47%
vs the sector median at left
Axsome Therapeutics, Inc.
Market Cap
$8.94B
Debt to Assets Ratio
28.79%
TTM Avg
32.24%
3Y Avg
32.87%
5Y Avg
32.74%
Market Cap
$8.97B
Debt to Assets Ratio
0.05%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.08B
Debt to Assets Ratio
0.37%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$8.75B
Debt to Assets Ratio
0.41%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
Market Cap
$9.78B
Debt to Assets Ratio
0.01%
TTM Avg
N/A
3Y Avg
N/A
5Y Avg
N/A
| NAME | MARKET CAP | DEBT TO ASSETS RATIO | TTM | 3Y | 5Y |
|---|---|---|---|---|---|
| Axsome Therapeutics, Inc. (AXSM) | $8.94B | 28.79% | 32.24% | 32.87% | 32.74% |
| Kymera Therapeutics, Inc. (KYMR)vs › | $8.97B | 0.05% | N/A | N/A | N/A |
| Caris Life Sciences, Inc. (CAI)vs › | $9.08B | 0.37% | N/A | N/A | N/A |
| Arrowhead Pharmaceuticals, Inc. (ARWR)vs › | $8.75B | 0.41% | N/A | N/A | N/A |
| Insulet Corp. (PODD)vs › | $9.37B | 0.30% | N/A | N/A | N/A |
| Oscar Health, Inc. (OSCR)vs › | $8.41B | 0.04% | N/A | N/A | N/A |
| Bruker Corporation (BRKRP)vs › | $9.57B | 0.32% | N/A | N/A | N/A |
| Henry Schein, Inc. (HSIC)vs › | $9.76B | 0.34% | N/A | N/A | N/A |
| Krystal Biotech, Inc. (KRYS)vs › | $9.78B | 0.01% | N/A | N/A | N/A |
| The Ensign Group, Inc. (ENSG)vs › | $9.95B | 0.39% | N/A | N/A | N/A |
Debt/Assets
28.8%
Debt/Equity
2.63
Current Ratio
1.43
Interest Coverage
-25.8x
Formula: Debt/Assets = Total Debt / Total Assets × 100
Debt/Assets vs Debt/Equity:
Industry context matters: Capital-intensive industries (utilities, real estate) typically have higher Debt/Assets ratios than tech companies.
Debt/Assets ratio shows what percentage of a company's assets are financed by debt. Compare the current value with the historical chart and peer group to understand leverage over time.
Expanded definitions: Investopedia, Wikipedia, Corporate Finance Institute
| DATE | DEBT TO ASSETS RATIO |
|---|---|
| 2026-06-30 | 28.79% |
| 2026-03-31 | 30.82% |
| 2025-12-31 | 34.98% |
| 2025-09-30 | 32.66% |
| 2025-06-30 | 33.97% |
| 2025-03-31 | 35.40% |
| 2024-12-31 | 33.94% |
| 2024-09-30 | 34.25% |
| 2024-06-30 | 34.99% |
| 2024-03-31 | 34.71% |
| 2023-12-31 | 31.68% |
| 2023-09-30 | 30.89% |
| 2023-06-30 | 30.20% |
| 2023-03-31 | 37.96% |
| 2022-12-31 | 28.56% |
| 2022-09-30 | 27.83% |
| 2022-06-30 | 52.15% |
| 2022-03-31 | 56.77% |
| 2021-12-31 | 56.63% |
| 2021-09-30 | 42.93% |
| 2021-06-30 | 34.94% |
| 2021-03-31 | 30.03% |
| 2020-12-31 | 26.93% |
| 2020-09-30 | 23.59% |
| 2020-06-30 | 10.62% |
| 2020-03-31 | 10.17% |
| 2019-12-31 | 9.04% |
| 2019-09-30 | 44.46% |
| 2019-06-30 | 35.74% |
| 2019-03-31 | 44.08% |
| 2018-12-31 | 44.94% |
| 2018-09-30 | 47.91% |
| 2018-06-30 | 38.99% |
| 2018-03-31 | 32.96% |
| 2017-12-31 | 27.93% |
| 2017-09-30 | 30.94% |
| 2017-06-30 | 25.54% |
| 2017-03-31 | 21.23% |
| 2016-12-31 | 25.49% |
| 2016-09-30 | 0.00% |
| 2016-06-30 | 0.00% |
| 2016-03-31 | 0.00% |
| 2015-12-31 | 0.00% |
| 2015-09-30 | 246.64% |
| 2015-06-30 | 158.67% |
| 2014-12-31 | 160.89% |
